Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers.

This study shows a significant difference in the choice of medications between pediatric rheumatologists practising in the two centres. Despite this, a high proportion of patients had inactive disease at 2 years and there was a low frequency of damage: modern treatments have improved outcomes.